Drugs / APG-157
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06011109 | Dec 2023 → Dec 2026 expected | glioblastoma | Aveta Biomics, Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05865028 | May 2023 → May 2027 expected | oral cavity carcinoma in situ | Elizabeth J Franzmann | Recruiting | No outcome recorded |
| Phase 2 | NCT05312710 | Apr 2022 → Dec 2026 expected | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Aveta Biomics, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07667296 | Jul 2026 → Dec 2031 expected | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Aveta Biomics, Inc. | Not yet recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05551013 | — | glioblastoma | Aveta Biomics, Inc. | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-04-09 | Aveta Biomics, Inc. | Results APG-157 Reduces HPV Viral Load and Activates Anti-Tumor Immunity in Head & Neck Cancer: Presentation at AACR 2026 avetabiomics.com ↗
Aveta Biomics, together with researchers from the VA Greater Los Angeles Healthcare System (VAGLAHS), announced new Phase 2A subpopulation data for APG-157 in head and neck squamous cell carcinoma (HNSCC) from patients at one of the clinical trial sites, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. |
| 2025-10-13 | Aveta Biomics, Inc. | Results Aveta Biomics to Present at the Upcoming 2025 ESMO Congress avetabiomics.com ↗ |
| 2025-04-30 | Aveta Biomics, Inc. | Results Aveta Biomics Announces Abstract Acceptance for Presentation at the 2025 ASCO Annual Meeting avetabiomics.com ↗
In our Phase IIA study, APG-157 demonstrated clinically meaningful activity across multiple key endpoints, including survival outcomes, with consistent benefits observed both in the overall patient population and in key subgroups. |
| 2024-08-22 | Aveta Biomics, Inc. | Regulatory FDA Grants Fast Track Designation to Aveta Biomics’ Drug APG-157 for Neoadjuvant Treatment of Head and Neck Cancer avetabiomics.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-09 | Aveta Biomics, Inc. | APG-157 Reduces HPV Viral Load and Activates Anti-Tumor Immunity in Head & Neck Cancer: Presentation at AACR 2026 avetabiomics.com ↗ |
| 2025-10-13 | Aveta Biomics, Inc. | Aveta Biomics to Present at the Upcoming 2025 ESMO Congress avetabiomics.com ↗ |
| 2025-04-30 | Aveta Biomics, Inc. | Aveta Biomics Announces Abstract Acceptance for Presentation at the 2025 ASCO Annual Meeting avetabiomics.com ↗ |
| 2024-08-22 | Aveta Biomics, Inc. | FDA Grants Fast Track Designation to Aveta Biomics’ Drug APG-157 for Neoadjuvant Treatment of Head and Neck Cancer avetabiomics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APG-157 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05865028 ↗ |
| Route | Oral | “orally administered APG-157” NCT05312710 ↗ |